Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
– As of
Year End 2023 Financial Results
-
As of
December 31, 2023 , Stoke had$201.4 million in cash, cash equivalents, and marketable securities, which is anticipated to fund operations to the end of 2025. -
Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the year ended
December 31, 2023 was$8.8 million , compared to$12.4 million , for the year endedDecember 31, 2022 . -
Net loss for the year ended
December 31, 2023 was$104.7 million , or$2.38 per share compared to$101.1 million , or$2.60 per share for 2022. -
Research and development expenses for the year ended
December 31, 2023 were$82.2 million , compared to$77.8 million for 2022. -
General and administrative expenses for the year ended
December 31, 2023 were$41.3 million , compared to$38.9 million for 2022. -
The increase in operating expenses for the year ended
December 31, 2023 compared to the same period in 2022 primarily relate to increases in costs associated with personnel, third party contracts, consulting, facilities and other costs associated with development activities for STK-001 and STK-002, research on additional therapeutics and growing a public corporation.
Fourth Quarter 2023 Financial Results
-
Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended
December 31, 2023 was$2.8 million , compared to$3.3 million , for the same period in 2022. -
Net loss for the three months ended
December 31, 2023 was$27.0 million , or$0.60 per share, compared to$25.7 million , or$0.65 per share, for the same period in 2022. -
Research and development expenses for the three months ended
December 31, 2023 were$21.8 million , compared to$21.1 million for the same period in 2022. -
General and administrative expenses for the three months ended
December 31, 2023 were$10.6 million , compared to$9.4 million for the same period in 2022. -
The increase in operating expenses for the three months ended
December 31, 2023 compared to the same period in 2022 primarily relate to increases in costs associated with personnel, third party contracts, consulting, facilities and others associated with development activities for STK-001 and STK-002, research on additional therapeutics and growing a public corporation.
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the Company’s cash runway. Statements including words such as “anticipate,” “plan,” “will,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause our results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risk and uncertainties related to: the Company’s ability to advance, obtain regulatory approval of, and ultimately commercialize its product candidates; the timing of data readouts and interim and final results of preclinical and clinical trials; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; preliminary interim data readouts of ongoing trials may show results that change when such trials are completed; the Company’s ability to fund development activities and achieve development goals into 2025; the Company’s ability to protect its intellectual property; the direct or indirect impact of global business, political and macroeconomic conditions, including inflation, interest rate volatility, cybersecurity events, uncertainty with respect to the federal budget, instability in the global banking system and volatile market conditions, and global events, including public health crises, and ongoing geopolitical conflicts, such as the conflicts in
Financial Tables Follow
| Consolidated balance sheets | ||||||||
| (in thousands, except share and per share amounts) | ||||||||
| As of |
||||||||
|
2023 |
2022 |
|||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents |
$ |
191,442 |
|
$ |
113,556 |
|
||
| Marketable securities |
|
9,952 |
|
|
116,039 |
|
||
| Prepaid expenses |
|
11,320 |
|
|
10,932 |
|
||
| Other current assets |
|
2,561 |
|
|
2,955 |
|
||
| Interest receivable |
|
64 |
|
|
588 |
|
||
| Total current assets |
$ |
215,339 |
|
$ |
244,070 |
|
||
| Restricted cash |
|
569 |
|
|
569 |
|
||
| Operating lease right-of-use assets |
|
6,611 |
|
|
4,753 |
|
||
| Property and equipment, net |
|
5,823 |
|
|
6,675 |
|
||
| Total assets |
$ |
228,342 |
|
$ |
256,067 |
|
||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable |
$ |
1,695 |
|
$ |
766 |
|
||
| Accrued and other current liabilities |
|
13,815 |
|
|
15,748 |
|
||
| Deferred revenue - current portion |
|
15,309 |
|
|
14,880 |
|
||
| Total current liabilities |
$ |
30,819 |
|
$ |
31,394 |
|
||
| Deferred revenue - net of current portion |
|
33,074 |
|
|
36,856 |
|
||
| Other long term liabilities |
|
4,884 |
|
|
2,968 |
|
||
| Total long term liabilities |
$ |
37,958 |
|
$ |
39,824 |
|
||
| Total liabilities |
$ |
68,777 |
|
$ |
71,218 |
|
||
| Stockholders’ equity | ||||||||
| Common stock, par value of |
|
5 |
|
|
4 |
|
||
| Additional paid-in capital |
|
561,433 |
|
|
483,170 |
|
||
| Accumulated other comprehensive loss |
|
(24 |
) |
|
(1,175 |
) |
||
| Accumulated deficit |
|
(401,849 |
) |
|
(297,150 |
) |
||
| Total stockholders’ equity |
$ |
159,565 |
|
$ |
184,849 |
|
||
| Total liabilities and stockholders’ equity |
$ |
228,342 |
|
$ |
256,067 |
|
||
| Consolidated statements of operations and comprehensive loss | ||||||||||||||||
| (in thousands, except share and per share amounts) | ||||||||||||||||
| Three months ended (unaudited) |
Year Ended |
|||||||||||||||
|
2023 |
2022 |
2023 |
2022 |
|||||||||||||
| Revenue |
$ |
2,801 |
|
$ |
3,269 |
|
$ |
8,780 |
|
$ |
12,405 |
|
||||
| Operating expenses: | ||||||||||||||||
| Research and development |
|
21,778 |
|
|
21,061 |
|
|
82,231 |
|
|
77,837 |
|
||||
| General and administrative |
|
10,610 |
|
|
9,383 |
|
|
41,322 |
|
|
38,924 |
|
||||
| Total operating expenses |
|
32,388 |
|
|
30,444 |
|
|
123,553 |
|
|
116,761 |
|
||||
| Loss from operations |
|
(29,587 |
) |
|
(27,175 |
) |
|
(114,773 |
) |
|
(104,356 |
) |
||||
| Other income (expense): | ||||||||||||||||
| Interest income (expense), net |
|
2,587 |
|
|
1,479 |
|
|
9,908 |
|
|
3,122 |
|
||||
| Other income (expense), net |
|
42 |
|
|
41 |
|
|
166 |
|
|
167 |
|
||||
| Total other income (expense) |
|
2,629 |
|
|
1,520 |
|
|
10,074 |
|
|
3,289 |
|
||||
| Net loss |
$ |
(26,958 |
) |
$ |
(25,655 |
) |
$ |
(104,699 |
) |
$ |
(101,067 |
) |
||||
| Net loss per share—basic and diluted |
$ |
(0.60 |
) |
$ |
(0.65 |
) |
$ |
(2.38 |
) |
$ |
(2.60 |
) |
||||
| Weighted average common shares outstanding—basic and diluted |
|
44,958,894 |
|
|
39,434,027 |
|
|
43,994,862 |
|
|
38,897,442 |
|
||||
| Comprehensive loss: | ||||||||||||||||
| Net loss |
$ |
(26,958 |
) |
$ |
(25,655 |
) |
$ |
(104,699 |
) |
$ |
(101,067 |
) |
||||
| Other comprehensive loss: | ||||||||||||||||
| Unrealized gain (loss) on marketable securities |
|
122 |
|
|
528 |
|
|
1,151 |
|
|
(1,007 |
) |
||||
| Total other comprehensive gain (loss) |
$ |
122 |
|
$ |
528 |
|
$ |
1,151 |
|
$ |
(1,007 |
) |
||||
| Comprehensive loss |
$ |
(26,836 |
) |
$ |
(25,127 |
) |
$ |
(103,548 |
) |
$ |
(102,074 |
) |
||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325008949/en/
Stoke Media & Investor Contacts:
Chief Communications Officer
dkalmar@stoketherapeutics.com
781-303-8302
Vice President, Investor Relations
IR@stoketherapeutics.com
617-312-2754
Source: